On this blog, we have been following two Celltrion biosimilars: CT-P10 (rituximab) and CT-P13 (infliximab, the subject of the Janssen v. Celltrion litigation).  According to a Celltrion press release, new data released today at the 2016 American College of Rheumatology (ACR) Annual Meeting show that the efficacy and safety profile of CT-P10 (rituximab) in rheumatoid arthritis patients is comparable to patients treated with originator rituximab over 24 weeks.  The study looked at both pharmacokinetic equivalence and pharmacodynamics.

Celltrion also presented data from the NOR-SWITCH study that we have previously reported on, which also found that patients could be safely switched from originator infliximab to CT-P13 without sacrificing efficacy or safety.

Stay tuned to Big Molecule Watch for more updates.